Dr Reddys Laboratories ADR Logo
US2561352038
659157
RDY

Dr Reddys Laboratories ADR

Loading quotes...

Forecast

The analysts' average price target is €13.01 (-2.55%). The median is €13.01 (-2.55%).

Buy
  6
Hold
  4
Sell
  2

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Dr Reddys Laboratories ADR has already paid €0.0722 in dividends. The last payout was in August.

Financials

In the last quarter, Dr Reddys Laboratories ADR had revenue of €796.95m and net profit of €85.02m
(EUR) September 2026
YoY
Revenue 796.95m 5.64%
Gross profit 415.48m 10.02%
Net profit 85.02m 38.33%
EBITDA 157.75m 32.34%

Fundamentals

Metric Value
Market capitalization
€11.14bn
Number of shares
833.54m
52-week high/low
€14.21 - €10.30
Dividend yield
0.54%
Dividends TTM
€0.0722
Beta
0.25
P/E ratio
41.07
PEG ratio
-0.79
P/B ratio
2.98
P/S ratio
3.49

Company profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and commercialization of differentiated formulations for dermatology and neurology therapeutic areas. The Others segment engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2021, it had three late stage projects at various stages of development. Its therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Name
Dr Reddys Laboratories ADR
CEO
Erez Israeli
Headquarters Hyderabad, ts
India
Website
Sector
Health Care
Industry
Pharmaceuticals
IPO
11/04/2001
Employees 27,527

Ticker symbols

Exchange Symbol
NYSE
RDY
Frankfurt
RDDA.F
Düsseldorf
RDDA.DU
München
RDDA.MU
🍪

Parqet  uses cookies. Learn more